Breast Screening Review Bibliography Bibliography to date - April ...

More documents

Recommendations

Info

Blanks RG, Moss SM et al Effect of NHS breast screening programme on mortality frombreast cancer in England and Wales, 1990-8: comparison of observed with predictedmortality, BMJ, 2000, 16;321:665-669Breast Screening Frequency Trial Group. The frequency of breast cancer screening: resultsfrom the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on CancerResearch. Eur J Cancer. 2002, 38(11):1458-64.Bulliard JL, Levi F. Mammography screening: time to re-evaluate its impact? Eur J CancerPrev. 2012 Jan 23. [Epub ahead of print]Burton RC, Bell RJ, Thiagarajah G, Stevenson C. Adjuvant therapy, not mammographicscreening, accounts for most of the observed breast cancer specific mortality reductions inAustralian women since the national screening program began in 1991. Breast Cancer ResTreat 2011; 29 Sep [Epub ahead of print].Canadian Task Force on Preventive Health Care, Recommendations on screening for breastcancer in average-risk women aged 40-74 years, CMAJ, 2011, 183 (17): 1991-2001Collaborative Group on Hormonal Factors in Breast Cancer, Familial breast cancer:collaborative reanalysis of individual data from 52 epidemiological studies including 58 209women with breast cancer and 101 986 women without the disease, 2001, The Lancet, 358:1389-1399Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients withductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' HealthStudy. Cancer, 2005, 103(9):1778-84Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTEinvestigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stagebreast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec;11(12):1135-41.Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS,George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductalcarcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011Jan;12(1):21-9.de Gelder R, Fracheboud J. Digital, mammography screening: Weighing reduced mortalityagainst increased overdiagnosis, Prev Med 2011 , 53 (3): 134-140de Gelder R, Heijnsdijk EA et al, Interpreting overdiagnosis estimates in population-basedmammography screening, Epidemiol Reviews, 2011, 33 (1): 111-121De Haes JCJM, de Koning H et al, The impact of a breast cancer screening programme onquality - adjusted life years, Int J Cancer, 1991, 49 (4), 538-5442
De Koning H, van Ineveld B et al, Breast Screening and cost effectiveness: Policy alternatives,quality of life considerations and the possible impact of uncertain factors, Int J Cancer, 1991,49(4), 531 - 537Duffy SW, Agbaje O et al, Overdiagnosis and overtreatment of breast cancer: estimates ofoverdiagnosis from two trials of mammographic screening for breast cancer, BCR, 2005, 7(6): 258-265Duffy SW, Interpretation of the breast screening trials: a commentary on the recent paperby Gøtzsche and Olsen. Breast, 2001, 10(3):209-12.Duffy SW, Lynge E et al, Complexities in the estimation of overdiagnosis in breast cancerscreening, BJC, 2008, 99 (7): 1176-1178Duffy SW, Tabar L et al, Absolute numbers of lives saved and overdiagnosis in breast cancerscreening, from a randomized trial and from the Breast Screening Programme in England, JMed Screen, 2010; 17: 25Duffy SW, Tabar L, Vitak B, Yen MF, Warwick J, Smith RA, Chen HH, The Swedish Two-CountyTrial of mammographic screening: cluster randomisation and end point evaluation. AnnOncol. 2003, 14(8):1196-8.Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostatecancer. JAMA. 2009 Oct 21;302(15):1685-92.Esserman L, Thompson I, Solving the overdiagnosis dilemma. J Natl Cancer Inst. 2010 May5;102(9):582-3.Fielder HM, Warwick J, et al A case-control study to estimate the impact on breast cancerdeath of the breast screening programme in Wales, J Med Screen, 2004, 11 (4): 194-198Frachebound J, Groenewould JH et al, Seventy-five years is an appropriate upper age limitfor population-based mammography screening, Int J Cancer, 2006, 118, 2020-2025Freedman DA, Petitti DB, Robins JM , On the efficacy of screening for breast cancer. Int JEpidemiol. 2004 Feb;33(1):43-55.Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact onbreast cancer mortality. Ann Oncol. 2005;16 Suppl 2:ii153-62.Gabe R, Tryggvadóttir L, A case-control study to estimate the impact of the Icelandicpopulation-based mammography screening program on breast cancer death, Acta Radiol,2007, 48 (9): 948-955Gelder R de, van As E et al, Breast cancer screening: Evidence for false reassurance? 2008,Int J Cancer, 123, 680-686Giordan L, von Karsa L, Mammographic screening programmes in Europe: organization,coverage and participation, J Med Screen, to be published in 20123
Page 1: Breast Screening Review Bibliograph
Page 5 and 6: Jørgensen KJ, Zahl PH et al, Overd
Page 7 and 8: Paci E, Warwick J et al, Overdiagno
Page 9 and 10: Zahl PH, Gøtzsche PC, Mæhlen J. N
Page 11: Moser K, Patnick J, Beral V. Inequa

Breast Screening Review Bibliography Bibliography to date - April ...

Create successful ePaper yourself

Delete template?

Save as template?